drugset / Trial / NCT06722417

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

NCT06722417

Phase 1 Completed 16 enrolled AbbVie
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the pharmacokinetics, safety, and tolerability of icalcaprant administered orally in healthy adult Japanese and Han Chinese participants.

Timeline

Start
2024-11-26
Primary completion
2025-01-17
Completion
2025-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Icalcaprant Small molecule Oral

Indications

No indication recorded.